Hongmei Wang

Dr. Hongmei Wang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
QLQing Li
Qing Li
NJNathan Johnston
Nathan Johnston
XZXiufen Zheng
Xiufen Zheng
HWHongmei Wang
Hongmei Wang
XZXusheng Zhang
Xusheng Zhang
WMWei-Ping Min
Wei-Ping Min
MiR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion

25 January 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YPYi Pan
Yi Pan
CYConglin Ye
Conglin Ye
QTQingshan Tian
Qingshan Tian
SYSongxin Yan
Songxin Yan
XZXiaoping Zeng
Xiaoping Zeng
HWHongmei Wang
Hongmei Wang
Although microRNA (miR)-145 has been identified to be a tumor suppressor in various types of tumor, it promotes the progression of non‑small cell lung cancer (NSCLC). However, the precise underlying molecular mechanism of its action remains unclear. The present study investigated the effects of miR‑145 on the proliferation, invasion, metastasis and apoptosis of the NSCLC A549 cell line and the underlying molecular mechanism of its action. In vitro cell proliferation, invasion, migration and apoptosis assays were employed, and the expression levels of matrix metalloproteinase (MMP)‑2, MMP‑9, B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X protein (Bax), caspase‑3and poly(ADP-ribose) polymerase (PARP) were evaluated by western blot analysis. The results demonstrated that ectopic expression of miR-145 inhibited the proliferation, invasion and migration of A549 cells, but promoted the apoptosis of A549 cells. Western blot analysis indicated that increased miR‑145 levels led to a marked decrease in the expression of MMP‑2, MMP‑9 and Bcl‑2. Upregulation of miR‑145 expression increased the expression of Bax, thus increasing the Bax/Bcl‑2 ratio. Additionally, the results indicated that miR‑145 over expression promoted the cleavage of caspase‑3 and PARP. Taken together, these results indicated that miR‑145 suppresses the proliferative, invasive and migratory ability of A549 cells. Additionally, miR‑145 upregulation induced apoptosis of A549 cells possibly by decreasing MMP‑2 and MMP‑9 expression, the Bax/Bcl‑2 ratio and the activity of the caspase-3 cascade.

12 November 2019 in Molecular Medicine Reports
Verified
Journal Article
Closed access
PDF file
MLMeng Liu
Meng Liu
ZLZiyang Li
Ziyang Li
WYWeirong Yao
Weirong Yao
XZXiaoping Zeng
Xiaoping Zeng
LWLingyun Wang
Lingyun Wang
HWHongmei Wang
Hongmei Wang
Previous studies suggest that radiotherapy (RT) can induce immune activation, which not only reduces the progression of tumors, but also causes the release of tumor antigens. The combination of RT and immune checkpoint blockade, such as the inhibition of programmed cell death 1 (PD‑1) and programmed cell death ligand 1 (PD‑L1), has been demonstrated to yield impressive response rates. However, a substantial proportion of patients develop resistance such therapies. Previous studies have shown that indoleamine 2,3‑dioxygenase (IDO) causes T cell exhaustion and increased formation of regulatory T cells (Tregs), upregulating the expression of inhibitory receptors and ligands. Therefore, the application of IDO inhibitors combined with RT may have a synergistic effect by relieving immunosuppression. Lewis lung cancer cell‑bearing mice were treated with the IDO inhibitor 1‑methyl‑tryptophan (1MT) and/or 10 Gy RT. Tumor size was measured every day, flow cytometry was performed to measure the expression of dendritic cell (DC) maturation markers, inhibitory receptors, ligands, cytotoxic T cells and Treg phenotypic markers. Reverse transcription‑quantitative PCR was used to evaluate the mRNA expression levels of IDO, PD‑L1, PD‑1, T cell immunoglobulin domain and mucin domain 3 (TIM‑3), B‑ and T‑lymphocyte attenuator (BTLA) and galectin‑9. Compared with the control group, treatment with 1MT or RT reduced tumor growth, however, the combination therapy was more effective than either treatment alone. Flow cytometry showed the upregulation of CD80, CD86 and the major histocompatibility complex II in spleen DCs and the concurrent downregulation of CD4, CD25 and forkhead box protein P3 in lymphocytes in the treatment groups. Compared with the control group, inhibitory receptors and ligands that affect DCs and T cells were observed, expression levels of PD‑L1, PD‑1, TIM‑3, BTLA and galectin‑9 are decreased in treatment group compared with control. IDO inhibition synergized with RT to downregulate Tregs, inhibitory receptors and ligands to prevent T cell exhaustion. By activating DCs and T cells, this combination therapy may strongly enhance antitumor immunity and inhibit tumor progression.

24 February 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
JZJianhao Zhan
Jianhao Zhan
JWJisheng Wang
Jisheng Wang
YLYuqing Liang
Yuqing Liang
LWLisha Wang
Lisha Wang
LHLe Huang
Le Huang
HWHongmei Wang
Hongmei Wang
Apoptosis plays a pivotal role in pathogen elimination and maintaining homeostasis. However, viruses have evolved strategies to evade apoptosis, enabling their persistence within the host. Z-DNA binding protein 1 (ZBP1) is a potent innate immune sensor that detects cytoplasmic nucleic acids and activates the innate immune response to clear pathogens. When apoptosis is inhibited by viral invasion, ZBP1 can be activated to compensate for the effect of apoptosis by triggering an innate immune response. This review examined the mechanisms of apoptosis inhibition and ZBP1 activation during viral invasion. The authors outlined the mechanisms of ZBP1-induced type I interferon, pyroptosis and necroptosis, as well as the crosstalk between ZBP1 and the cGAS-STING signalling pathway. Furthermore, ZBP1 can reverse the suppression of apoptotic signals induced by viruses. Intriguingly, a positive feedback loop exists in the ZBP1 signalling pathway, which intensifies the innate immune response while triggering a cytokine storm, leading to tissue and organ damage. The prudent use of ZBP1, which is a double-edged sword, has significant clinical implications for treating infections and inflammation.

18 June 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
CYCongyi Yang
Congyi Yang
RZRuiqian Zhang
Ruiqian Zhang
HLHui Lin
Hui Lin
HWHongmei Wang
Hongmei Wang

13 February 2014 in Inflammation
Verified
Journal Article
Closed access
PDF file
YHYong-Hong Huang
Yong-Hong Huang
HWHongmei Wang
Hongmei Wang
ZCZhen-Yu Cai
Zhen-Yu Cai
FXFang-Yun Xu
Fang-Yun Xu
XZXiaoyan Zhou
Xiaoyan Zhou